Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness.

Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon."

"We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention."

"It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free."

#MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment

medicuspharma.com

Listen to the podcast here